


Respectfully submitted,  
COHEN, PONTANI, LIEBERMAN & PAVANE

By:   
 Vincent M. Fazzari  
 Reg. No. 26,879  
 551 Fifth Avenue, Suite 1210  
 New York, N.Y. 10176  
 (212) 687-2770

30 March 2001

**VERSION WITH MARKINGS TO SHOW CHANGES MADE**

**In the specification:**

Refer to the English language translation, page 3 between the title and the first line of text insert as a heading as follows:

**--Background of the Invention--;**

Line 7 from the bottom, following "symptoms" and "vomiting" in each instance insert --, --;

Migraine is understood today as a complex functional disturbance of neuronal and vascular elements of the CNS. The headaches associated with it are apparently induced by an aseptic inflammation of the blood vessels and the dura mater vessels of the brain in association with permeability of the vessel walls for albumin and the release of neurotransmitters such as serotonin and tryptamine. The disorder is characterized by the following sequence of events: vasodilation, activation of the trigeminus, and neurogenic inflammation. Migraine attacks occur abruptly and repeatedly. They involve headaches on one side of the head, which can be associated with various accompanying phenomena: autonomic symptoms such as nausea and vomiting, aversion to light and noise, visual symptoms such as disturbed vision, and also neurological breakdowns such as paralysis or disturbances in language or speech. The symptoms, nausea and vomiting, are caused by the absence of gastrointestinal peristalsis. Most (70%) migraine patients are women. They are more likely to suffer migraine during their menstrual periods. The treatment of migraine has been limited so far to the treatment of the headaches as a way of relieving the patient's discomfort. A more effective and improved

treatment of migraine by means of phytopharmaceutical preparations to address the other symptoms of migraine is not known.

Page 5, above the first line of text insert as a heading as follows:

**--The Invention--;**

Page 8, following the last line of text insert as a separate paragraph the following:

--The terms and expressions which have been employed are used as terms of description and not of limitation, and there is no intention in the use of such terms and expressions of excluding any equivalent of the features shown and described or portions thereof, it being recognized that various modifications are possible within the scope of the invention.--

**In the Abstract:**

Following page 11, insert as a new page the following abstract:

**--Abstract**

The invention relates to pharmaceutical combination preparations with synergistic action for the treatment of migraine. Said preparations contain plant-based components and/or preparations of *Tanacerum parthenium* in combination with *Vitex agnus castus* and/or *Cimicifuga racemosa* and/or *Zingiber officinale* as their pharmaceutically active ingredients. The combination preparation provided for in the invention is suitable for the treatment of not only the headache but also the other symptoms of migraine while avoiding the usual side-effects.--

09306558 033004  
"B5990860"